p53 Status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen

A. Gadducci, C. Cianci, S. Cosio, F. Carnino, A. Fanucchi, F. Buttitta, P. F. Conte, A. R. Genazzani

Research output: Contribution to journalArticle

Abstract

Background: The aim of this study was to assess the relationship between p53 status and the clinical outcome of patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Patients and Methods: The investigation was conducted on 38 patients with FIGO stage III-IV ovarian cancer from whom rumor tissue samples for p53 protein immunostaining were obtained during initial cytoreductive surgery. All these patients subsequently received six cycles of first-line combination chemotherapy with paclitaxel 175 mg/m2 (3-hour infusion) plus carboplatin AUC 6 with or without epidoxorubicin 75 mg/m2. Results: Positive p53 immunostaining was detected in tissue samples collected from 24 (63.2%) ovarian cancers. A clinical complete response was obtained in 14 (58.3%) of the 24 patients with positive p53 immunostaining compared to 9 (64.3%) of the 14 patients with negative p53 immunostaining (p=0.717). A pathological complete response was found in 6 (25.0%) of the former compared to 4 (28.6%) of the latter (p=0.956). Similarly, survival did not correlate with p53 status (p=0.1271). Discussion: p53 status seems to be neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. These results are consistent with experimental data showing that paclitaxel cytotoxicity in ovarian cancer is likely to be mediated by a p53-independent pathway.

Original languageEnglish
Pages (from-to)4793-4799
Number of pages7
JournalAnticancer Research
Volume20
Issue number6 C
Publication statusPublished - 2000

Keywords

  • Chemotherapy
  • Ovarian cancer
  • p53 gene
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'p53 Status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen'. Together they form a unique fingerprint.

  • Cite this

    Gadducci, A., Cianci, C., Cosio, S., Carnino, F., Fanucchi, A., Buttitta, F., Conte, P. F., & Genazzani, A. R. (2000). p53 Status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Research, 20(6 C), 4793-4799.